Summit Therapeutics (SMMT) stock, explained like you're 5

Is Summit Therapeutics a small, medium or large cap company?

Yes. Summit Therapeutics is a large cap stock. Its market cap, which is the total value of all its shares, is about 14.1 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Summit Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves SMMT stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus (Yahoo Finance)
• SMMT Stock Heads For Third Straight Weekly Drop Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data (Stocktwits)
• How Investors Are Reacting To Summit Therapeutics Stock Phase III Cancer Trial Collaboration (Simply Wall Street)
• Accounting chief gets a stock grant at Summit Therapeutics (SMMT), vesting in 2029 if still employed. (Stock Titan)
• Bernstein reiterates Summit Therapeutics stock rating on trial concerns (Investing.com)

Key terms to know before you follow SMMT

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility